Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs CVS Health Corp (CVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs CVS Health Corp — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.36, while CVS Health Corp trades at $93.49 (market cap $122.36B). The key difference: CVS Health Corp pays a 2.78% dividend while Bitwise Crypto Industry Innovators ETF pays none, and CVS Health Corp is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | CVS | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $110.60 |
52-Week Low | $16.74 | $64.88 |
Market Cap | — | $122.36B |
Enterprise Value | — | $184.71B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.88, up 1.42% today, but faces strong technical headwinds with 17 sell signals versus 0 buy signals across moving averages and oscillators. The stock shows bearish momentum with key resistance at $23 and support at $22. Financial metrics remain unavailable in current data, requiring verification through SEC filings.
The technical outlook appears bearish with weak momentum indicators. Investment opportunity depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and lack of visible fundamental support until financial disclosures are updated.
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →
